Huajun Yang, Zhongliang Li, Beibei Tang, Danting Yan, Weibin Tan*, Xiaoyan Fu*, Frank Xing, and Qian Shi
*Suzhou Blood Center Taicang , Jiangsu, China
Most human tumors express CD47 to escape macrophage surveillance. Therefore targeting CD47 to reinstate macrophage functionality in clearing tumor cells is an important immuno-oncology strategy.
To support research into novel anti-CD47 agents, robust preclinical platforms including in vitro assays are required. Crown Bioscience has consequently developed a macrophage differentiation system followed by M1/M2 activation.
This assay co-cultures activated macrophages with target tumor cells and labeling for flow cytometry, allowing the phagocytic effects of anti-CD47 agents and other related immunotherapeutics to be assessed.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-02-19
2021-10-29
landing_page
PDX/Databases